STEP THERAPY CRITERIA

This list is current as of 12/01/2019 and pertains to the following formularies:

<table>
<thead>
<tr>
<th>Formulary</th>
<th>Version</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019 Independent Health’s Medicare Advantage Individual Part D Formulary</td>
<td>39</td>
</tr>
<tr>
<td>2019 Independent Health’s Medicare Advantage Employer Group’s Part D Formulary</td>
<td>39</td>
</tr>
</tbody>
</table>

In some cases, we require that you first try certain drugs to treat your medical condition before we will cover another drug for that condition. For example, if Drug A and Drug B both treat your medical condition, we may not cover Drug B unless you try Drug A first. If Drug A does not work for you, we will then cover Drug B. This document contains the Step Therapy protocols that are associated with our Medicare Advantage Part D Formularies.

If you have any questions, please contact our Medicare Member Services Department at 1-800-665-1502 or, for TTY users 711, October 1st – March 31st: Monday through Sunday from 8 a.m. to 8 p.m., April 1st – September 30th: Monday through Friday from 8 a.m. to 8 p.m.

Independent Health is a Medicare Advantage organization with a Medicare contract offering HMO, HMO-SNP, HMO-POS and PPO plans. Enrollment in Independent Health depends on contract renewal.

The formulary may change at any time. You will receive notice when necessary.

Y0042_PH418 FYI 06152018
Aliskiren Step

Products Affected

- aliskiren fumarate tablet 150 mg oral
- aliskiren fumarate tablet 300 mg oral
- TEKTURNA HCT TABLET 150-12.5 MG ORAL
- TEKTURNA HCT TABLET 150-25 MG ORAL
- TEKTURNA HCT TABLET 300-12.5 MG ORAL
- TEKTURNA HCT TABLET 300-25 MG ORAL

Details

| Criteria | Prior prescription history of an ARB to obtain any products containing aliskiren. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.
### Doxercalciferol Step

**Products Affected**
- doxercalciferol capsule 0.5 mcg oral
- doxercalciferol capsule 1 mcg oral
- doxercalciferol capsule 2.5 mcg oral

**Details**

| Criteria                                      | Prior prescription history includes past use of calcitriol. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.
## GLP-1 Step

**Products Affected**

- BYDUREON BCISE AUTO-INJECTOR 2 MG/0.85ML SUBCUTANEOUS
- BYDUREON PEN-INJECTOR 2 MG SUBCUTANEOUS
- BYDUREON SUSPENSION RECONSTITUTER 2 MG SUBCUTANEOUS
- BYETTA 10 MCG PEN SOLUTION PEN-INJECTOR 10 MCG/0.04ML SUBCUTANEOUS
- BYETTA 5 MCG PEN SOLUTION PEN-INJECTOR 5 MCG/0.02ML SUBCUTANEOUS
- OZEMPIC (0.25 OR 0.5 MG/DOSE) SOLUTION PEN-INJECTOR 2 MG/1.5ML SUBCUTANEOUS
- OZEMPIC (1 MG/DOSE) SOLUTION PEN-INJECTOR 2 MG/1.5ML SUBCUTANEOUS
- RYBELSUS TABLET 14 MG ORAL
- RYBELSUS TABLET 3 MG ORAL
- RYBELSUS TABLET 7 MG ORAL
- TANZEUM PEN-INJECTOR 30 MG SUBCUTANEOUS
- TANZEUM PEN-INJECTOR 50 MG SUBCUTANEOUS
- TRULICITY SOLUTION PEN-INJECTOR 0.75 MG/0.5ML SUBCUTANEOUS
- TRULICITY SOLUTION PEN-INJECTOR 1.5 MG/0.5ML SUBCUTANEOUS
- VICTOZA SOLUTION PEN-INJECTOR 18 MG/3ML SUBCUTANEOUS

### Details

| Criteria | Prior prescription history includes concurrent use of metformin, a sulfonylurea, a DPP-4, or a TZD before a GLP-1 agonist. Step therapy does not apply when written by endocrinologist. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.
Mirvaso Step

Products Affected
• MIRVASO GEL 0.33 % EXTERNAL

Details

| Criteria                                      | Prior prescription history positive for the use of azelaic acid. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.
# Nexium Packet Step

## Products Affected
- NEXIUM PACKET 10 MG ORAL
- NEXIUM PACKET 2.5 MG ORAL
- NEXIUM PACKET 20 MG ORAL
- NEXIUM PACKET 40 MG ORAL
- NEXIUM PACKET 5 MG ORAL

## Details

| Criteria | Prior prescription history includes use of omeprazole or pantoprazole except for NSAID-induced gastric ulcer prophylaxis or treatment. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.
Paricalcitol/Rayaldee Step

Products Affected

• paricalcitol capsule 1 mcg oral
• paricalcitol capsule 2 mcg oral
• paricalcitol capsule 4 mcg oral

• RAYALDEE CAPSULE EXTENDED RELEASE 30 MCG ORAL

Details

| Criteria | Prior prescription history includes past use of calcitriol. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.
Rocklatan Step

Products Affected

- ROCKLATAN SOLUTION 0.02-0.005 % OPTHALMIC

Details

| Criteria | Prior prescription history positive for the use of an ophthalmic prostaglandin inhibitor. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.
Tramadol ER Biphasic Step

Products Affected
- tramadol hcl er (biphasic) tablet extended release 24 hour 100 mg oral
- tramadol hcl er (biphasic) tablet extended release 24 hour 200 mg oral
- tramadol hcl er (biphasic) tablet extended release 24 hour 300 mg oral
- tramadol hcl er capsule extended release 24 hour 100 mg oral
- tramadol hcl er capsule extended release 24 hour 150 mg oral
- tramadol hcl er capsule extended release 24 hour 200 mg oral
- tramadol hcl er capsule extended release 24 hour 300 mg oral

Details

| Criteria | Requires the use of an immediate-release tramadol product or non-biphasic extended-release tramadol first. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.
INDEX

aliskiren fumarate tablet 150 mg oral........... 1
aliskiren fumarate tablet 300 mg oral........... 1
BYDUREON BCISE AUTO-INJECTOR 2 MG/0.85ML SUBCUTANEOUS.................. 3
BYDUREON PEN-INJECTOR 2 MG SUBCUTANEOUS.............................................3
BYDUREON SUSPENSION RECONSTITUTED ER 2 MG SUBCUTANEOUS.........................3
BYETTA 10 MCG PEN SOLUTION PEN-INJECTOR 10 MCG/0.04ML SUBCUTANEOUS.............................................3
doxercalciferol capsule 0.5 mcg oral.............. 2
doxercalciferol capsule 1 mcg oral................. 2
doxercalciferol capsule 2.5 mcg oral................ 2
MIRVASO GEL 0.33 % EXTERNAL.................... 4
NEXIUM PACKET 10 MG ORAL....................... 5
NEXIUM PACKET 2.5 MG ORAL...................... 5
NEXIUM PACKET 20 MG ORAL....................... 5
NEXIUM PACKET 40 MG ORAL........................ 5
NEXIUM PACKET 5 MG ORAL.......................... 5
OZEMPIC (0.25 OR 0.5 MG/DOSE) SOLUTION PEN-INJECTOR 2 MG/1.5ML SUBCUTANEOUS.............................................3
OZEMPIC (1 MG/DOSE) SOLUTION PEN-INJECTOR 2 MG/1.5ML SUBCUTANEOUS......3
paricalcitol capsule 1 mcg oral.................... 6
paricalcitol capsule 2 mcg oral.................... 6
paricalcitol capsule 4 mcg oral.................... 6
RAYALDEE CAPSULE EXTENDED RELEASE 30 MCG ORAL................................. 6
ROCKLATAN SOLUTION 0.02-0.005 % OPTHALMIC.............................................7
RYBELSUS TABLET 14 MG ORAL..................... 3
RYBELSUS TABLET 3 MG ORAL..................... 3
RYBELSUS TABLET 7 MG ORAL..................... 3
TANZEUM PEN-INJECTOR 30 MG SUBCUTANEOUS................................. 3
TANZEUM PEN-INJECTOR 50 MG SUBCUTANEOUS................................. 3
TEKTURNA HCT TABLET 150-12.5 MG ORAL.. 1
TEKTURNA HCT TABLET 150-25 MG ORAL..... 1
tramadol hcl er (biphasic) tablet extended release 24 hour 100 mg oral................ 8
tramadol hcl er (biphasic) tablet extended release 24 hour 200 mg oral................ 8
tramadol hcl er (biphasic) tablet extended release 24 hour 300 mg oral................ 8
tramadol hcl er capsule extended release 24 hour 100 mg oral...................... 8
tramadol hcl er capsule extended release 24 hour 200 mg oral...................... 8
tramadol hcl er capsule extended release 24 hour 300 mg oral...................... 8
TRULICITY SOLUTION PEN-INJECTOR 0.75 MG/0.5ML SUBCUTANEOUS.................. 3
TRULICITY SOLUTION PEN-INJECTOR 1.5 MG/0.5ML SUBCUTANEOUS.................. 3
VICTOZA SOLUTION PEN-INJECTOR 18 MG/3ML SUBCUTANEOUS...................... 3